Io Therapeutics, Inc.

University of Texas System

Dartmouth College

Lo Therapeutics, Inc.

Martin E Sanders

Roshantha A Chandraratna

Vidyasagar Pradeep Vuligonda

Powel H Brown

Randolph J Noelle

Ethan Dmitrovsky

Elizabeth Nowak

Shanming Kuang

Cassandra Moyer

Abhijit Mazumdar

Harsh Shailesh Shah

The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.

Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists

Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, including a Tris salt form of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses.

RXR agonist salt form, polymorphs thereof, and uses thereof

The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.

Methods of using RARγ agonists for cancer treatment

The present specification provides combinations of active agents for the improved treatment of Her2cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

Use of an RXR agonist in treating drug resistant HER2+ cancers

The present specification provides improved methods of treating Her2cancers in which an RXR agonist and a taxane are administered to a subject having a Her2cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.

Use of an RXR agonist and taxanes in treating Her2+ cancers

Methods of using RAR&#x3b3; agonists for cancer treatment

Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

RAR selective agonists in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.

Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.

Treatment of disease with esters of selective RXR agonists

The present specification provides combinations of active agents for the improved treatment of Her2cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

Growing community of inventors

Seattle, WA, United States of America

Martin E Sanders